Key Points
- CEO Jacob Chacko sold 33,374 Oric shares on Dec. 16 at an average of $9.06 for ~$302,368, leaving him with 581,711 shares and a 5.43% reduction in ownership; he has executed multiple large sales since September (including 125,000 shares on Sept. 22).
- ORIC stock recently traded near $8.22 (50-day MA $11.94) with a market cap of about $800M, and analysts remain broadly positive — consensus rating "Moderate Buy" with an average target of $19.67 and several firms raising targets into the $20–$25 range.
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 10,720 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the completion of the transaction, the chief financial officer directly owned 68,148 shares in the company, valued at $617,420.88. The trade was a 13.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Dominic Piscitelli also recently made the following trade(s):
- On Monday, October 6th, Dominic Piscitelli sold 11,000 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $14.52, for a total transaction of $159,720.00.
Oric Pharmaceuticals Stock Performance
ORIC traded up $0.11 on Thursday, reaching $8.33. The company had a trading volume of 153,384 shares, compared to its average volume of 1,170,183. Oric Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.93. The stock has a market cap of $811.26 million, a P/E ratio of -4.80 and a beta of 1.32. The company's fifty day moving average is $11.94 and its 200 day moving average is $10.98.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.08. On average, sell-side analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on ORIC. Wall Street Zen downgraded Oric Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Sunday, November 23rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Oric Pharmaceuticals in a report on Wednesday, October 8th. Wolfe Research started coverage on shares of Oric Pharmaceuticals in a research report on Tuesday, November 18th. They issued a "peer perform" rating for the company. Oppenheimer raised their price target on shares of Oric Pharmaceuticals from $12.00 to $15.00 and gave the stock an "outperform" rating in a research report on Friday, November 14th. Finally, Wedbush reissued an "outperform" rating and issued a $20.00 price objective on shares of Oric Pharmaceuticals in a report on Monday, December 8th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $19.67.
Get Our Latest Research Report on Oric Pharmaceuticals
Institutional Investors Weigh In On Oric Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its stake in Oric Pharmaceuticals by 17,300.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company's stock worth $25,000 after buying an additional 2,422 shares in the last quarter. Assetmark Inc. acquired a new position in shares of Oric Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Oric Pharmaceuticals by 36.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,755 shares of the company's stock worth $45,000 after acquiring an additional 1,009 shares during the period. ANTIPODES PARTNERS Ltd boosted its position in shares of Oric Pharmaceuticals by 35.9% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company's stock worth $53,000 after acquiring an additional 1,372 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Oric Pharmaceuticals during the 3rd quarter worth approximately $60,000. Institutional investors own 95.05% of the company's stock.
Oric Pharmaceuticals Company Profile
(
Get Free Report)
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
